menu

Fight COVID-19 with Neutralizing mAbs

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Fight COVID-19 with Neutralizing mAbs

close
0.75 credits
45 minutes

CME/CE Broadcast Replay

Fight COVID-19 with Neutralizing mAbs
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution 
    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.  

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Leah Johnson, Lily Zurkovsky, PhD
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, Bernadette Marie Makar, MSN, APRN, BC, NP-C, and Dorothy Duffy, BS Pharmacy
    • Faculty: Tesha Seabra, MSN, RN and Mimi Secor, DNP, FNP-BC, FAANP 

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty: Robert Gottlieb, MD, PhD

    • Advisory Board: Eli Lilly and GSK

    Faculty: Marilyn Bulloch, PharmD, BCPS, FCCM

    • Speaker: Genentech
  • Target Audience

    This activity is designed for US healthcare providers involved in the care and treatment of patients with COVID-19 in outpatient settings, including physicians, nurse practitioners (NPs), physician assistants (PAs), registered nurses, and clinical pharmacists.

  • Learning Objectives

    As a result of participation in the proposed educational initiative, participants should be able to

    1. Identify appropriate patients with COVID-19 who can benefit from early treatment with neutralizing mAb therapies 
    2. Discuss the new treatment paradigm and underlying evidence for mild to moderate COVID-19 in ambulatory patients
    3. Overcome challenges to the preparation, administration, and monitoring of neutralizing mAb therapies for the treatment of COVID-19
    4. Collaborate to remove barriers for the use of neutralizing mAb therapies
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nurses
    Credit being awarded: 0.75 ANCC contact hours

    Nurse Practitioners

    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 0.75 contact hour(s) (which includes 0.75 hour(s) of pharmacology).

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.75 contact hours.

  • CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

    The content of this activity was independently peer reviewed by 2 reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative and AKH Inc.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.

  • Disclosure of Conflicts of Interest

    Disclosure and Conflict of Interest Resolution 
    Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.  

    *The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies – unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

    The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

    • Planners (Forefront Collaborative): Leah Johnson, Lily Zurkovsky, PhD
    • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, Bernadette Marie Makar, MSN, APRN, BC, NP-C, and Dorothy Duffy, BS Pharmacy
    • Faculty: Tesha Seabra, MSN, RN and Mimi Secor, DNP, FNP-BC, FAANP 

    The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

    Faculty: Robert Gottlieb, MD, PhD

    • Advisory Board: Eli Lilly and GSK

    Faculty: Marilyn Bulloch, PharmD, BCPS, FCCM

    • Speaker: Genentech
  • Target Audience

    This activity is designed for US healthcare providers involved in the care and treatment of patients with COVID-19 in outpatient settings, including physicians, nurse practitioners (NPs), physician assistants (PAs), registered nurses, and clinical pharmacists.

  • Learning Objectives

    As a result of participation in the proposed educational initiative, participants should be able to

    1. Identify appropriate patients with COVID-19 who can benefit from early treatment with neutralizing mAb therapies 
    2. Discuss the new treatment paradigm and underlying evidence for mild to moderate COVID-19 in ambulatory patients
    3. Overcome challenges to the preparation, administration, and monitoring of neutralizing mAb therapies for the treatment of COVID-19
    4. Collaborate to remove barriers for the use of neutralizing mAb therapies
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation Statement
    Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nurses
    Credit being awarded: 0.75 ANCC contact hours

    Nurse Practitioners

    This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 0.75 contact hour(s) (which includes 0.75 hour(s) of pharmacology).

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.75 contact hours.

  • CME Content Review

    The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

    The content of this activity was independently peer reviewed by 2 reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

    This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative and AKH Inc.

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 5/13/21